NCT01802476View on ClinicalTrials.gov

A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Healthy
Interventions
DRUG

Oral Drug Formulation of PD-0332991

Treatment A consists of a single 125 mg oral dose of PD-0332991.

DRUG

Intravenous Formulation of PD-0332991

Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.

Trial Locations (1)

NG11 6JS

Pfizer Investigational Site, Nottingham

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01802476 - A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991) | Biotech Hunter | Biotech Hunter